KORU Medical Systems (NASDAQ:KRMD – Get Free Report) and Nyxoah (NASDAQ:NYXH – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.
Insider and Institutional Ownership
58.6% of KORU Medical Systems shares are held by institutional investors. 20.6% of KORU Medical Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
KORU Medical Systems has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| KORU Medical Systems | 1 | 1 | 3 | 1 | 2.67 |
| Nyxoah | 1 | 0 | 3 | 0 | 2.50 |
KORU Medical Systems currently has a consensus target price of $6.13, indicating a potential upside of 28.41%. Nyxoah has a consensus target price of $11.67, indicating a potential upside of 211.11%. Given Nyxoah’s higher possible upside, analysts plainly believe Nyxoah is more favorable than KORU Medical Systems.
Valuation and Earnings
This table compares KORU Medical Systems and Nyxoah”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| KORU Medical Systems | $33.65 million | 6.57 | -$6.07 million | ($0.08) | -59.63 |
| Nyxoah | $4.89 million | 26.12 | -$64.10 million | ($2.49) | -1.51 |
KORU Medical Systems has higher revenue and earnings than Nyxoah. KORU Medical Systems is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares KORU Medical Systems and Nyxoah’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| KORU Medical Systems | -9.49% | -22.43% | -13.86% |
| Nyxoah | -1,457.97% | -101.99% | -66.74% |
Summary
KORU Medical Systems beats Nyxoah on 10 of the 14 factors compared between the two stocks.
About KORU Medical Systems
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Receive News & Ratings for KORU Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KORU Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
